trastuzumab (Herceptin®)

DRUG4 trials

Sponsors

Hoffmann-La Roche, University of Michigan Rogel Cancer Center, Bristol-Myers Squibb, M.D. Anderson Cancer Center

Conditions

Advanced CancersBreast Cancer

Phase 1

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

TerminatedNCT00726180

University of Michigan Rogel Cancer CenterBreast Cancer

Start: 2008-07-31End: 2010-10-31Updated: 2013-10-15

Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer

CompletedNCT00788333

Bristol-Myers SquibbBreast Cancer

Start: 2009-07-31End: 2011-11-30Updated: 2012-07-13

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

CompletedNCT01454804

M.D. Anderson Cancer CenterAdvanced Cancers

Start: 2011-10-31End: 2015-03-31Updated: 2016-04-13

Phase 3

A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer

CompletedNCT00022672

Hoffmann-La RocheBreast Cancer

Start: 2001-01-31End: 2009-10-31Updated: 2013-06-13

Related Papers

Outcomes of patients with advanced sarcoma enrolled in clinical trials of pazopanib in combination with histone deacetylase, mTOR, Her2, or MEK inhibitors.

Journal of Clinical Oncology2016-05-203 citations